The European Medicines Agency has accepted for review Organon’s application for its Henlius-partnered Perjeta (pertuzumab) biosimilar, paving the way for approval in a major global market.
The Perjeta biosimilar was the subject of a $100m+ deal between Organon and the Chinese company Shanghai Henlius Biotech signed in June 2022. At the time, Organon agreed to pay...